JPRN-UMIN000009155Completed未知
Tamoxifen Response by CYP2D6 Genotype-Based Treatment in Patients with Metastatic or Recurrent Breast Cancer - TARGET-1 study
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Enrollment
- 186
Study Overview
Brief Summary
Between December 2012 and July 2016, 186 patients were enrolled in Japan.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- Female
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) HER2 status positive 2) Prior endocrine therapy for recurrent or metastatic disease 3) Prior chemotherapy for recurrent or metastatic disease 4) Patients having active double cancer 5) Patients having CNS metastasis 6) Patients receiving continuous systemic administration of steroids 7) Patients receiving prohibited concomitant medications 8) Patients having difficulty to enroll to the study for psychiatric reasons 9) Patients who are pregnant (or might be pregnant), nursing, or those who will not use contraceptive methods 10) Other cases determined as being unsuitable by the investigators
Investigators
Similar Trials
Completed
Not Applicable
Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast CancerBreast CancerNCT00717015National University Hospital, Singapore
Unknown
Not Applicable
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian PopulationBreast CancerNCT05501158Nalagenetics Pte Ltd150
Completed
Not Applicable
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast CancerBreast NeoplasmsTamoxifenNCT00830973Medco Health Solutions, Inc.184
Unknown
Not Applicable
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer PatientsBreast CancerNCT00815555Assaf-Harofeh Medical Center500
Completed
Not Applicable
Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen LevelsER+ Breast CancerNCT04312347Nalagenetics Pte Ltd151